May 8, 2024
BULLETIN FROM ANNUAL GENERAL MEETING
IN ISOFOL MEDICAL AB (PUBL) HELD ON MAY 8, 2024
March 19, 2024
ISOFOL’S JAPANESE PARTNER SOLASIA INTENSIFIES ITS COMMITMENT TO THE CLINICAL DEVELOPMENT OF ARFOLITIXORIN
This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- August 21, 2024 - August 21, 2024
Interim report January-June 2024 - November 12, 2024 - November 12, 2024
Interim report June-September 2024
Media – Lates pressreleases
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024
Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (“AGM”) at which the…
Isofol Medical AB (publ) publishes interim report, January–March 2024
GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2024 is…
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
